Toll Like Receptor 4 - Pipeline Review, H1 2020

June 2020 | 131 pages | ID: T21CFA94226CEN
Global Markets Direct

Abstracts

Toll Like Receptor 4 - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Toll Like Receptor 4 – Pipeline Review, H1 2020'; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 4 (hToll or CD284 or TLR4) – Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).

The report 'Toll Like Receptor 4 – Pipeline Review, H1 2020' outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 4, 15 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Respiratory, Central Nervous System, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Coronavirus Disease 2019 (COVID-19), Non Alcoholic Fatty Liver Disease (NAFLD), Inflammation, Solid Tumor, Acute Lung Injury, Acute Respiratory Distress Syndrome, Atherosclerosis, Chronic Liver Disease, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Pain, Sepsis, Acute Ischemic Stroke, Acute Liver Failure, Alzheimer's Disease, Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Cyst, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Hearing Disorders, Hepatic Injury, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Pandemic Influenza, Peritonitis, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rheumatoid Arthritis, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified Rare Disease and Viral Respiratory Tract Infection.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
• The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
• The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by 13therapeutics Inc, H1 2020
Pipeline by Allodynic Therapeutics LLC, H1 2020
Pipeline by Aluda Pharmaceuticals Inc, H1 2020
Pipeline by Apollo Therapeutics LLC, H1 2020
Pipeline by AptaTargets SL, H1 2020
Pipeline by Ayuvis Research Inc, H1 2020
Pipeline by Batu Biologics Inc, H1 2020
Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, H1 2020
Pipeline by Cyxone AB, H1 2020
Pipeline by Douleur Therapeutics Inc, H1 2020
Pipeline by Edesa Biotech Inc, H1 2020
Pipeline by Eisai Co Ltd, H1 2020
Pipeline by eTheRNA Immunotherapies NV, H1 2020
Pipeline by EyeGene Inc, H1 2020
Pipeline by FasCure Therapeutics LLC, H1 2020
Pipeline by Immunovo BV, H1 2020
Pipeline by Inimmune Corp, H1 2020
Pipeline by Kupando GmbH, H1 2020
Pipeline by Lubris Biopharma, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Pattern Pharma Inc, H1 2020
Pipeline by Protara Therapeutics Inc, H1 2020
Pipeline by Soligenix Inc, H1 2020
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Pipeline by Vascular Biogenics Ltd, H1 2020
Pipeline by Xalud Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

13therapeutics Inc
Allodynic Therapeutics LLC
Aluda Pharmaceuticals Inc
Apollo Therapeutics LLC
AptaTargets SL
Ayuvis Research Inc
Batu Biologics Inc
Beijing Fogangren Bio-Pharm Tech Co Ltd
Cyxone AB
Douleur Therapeutics Inc
Edesa Biotech Inc
Eisai Co Ltd
eTheRNA Immunotherapies NV
EyeGene Inc
FasCure Therapeutics LLC
Immunovo BV
Inimmune Corp
Kupando GmbH
Lubris Biopharma
Merck & Co Inc
Pattern Pharma Inc
Protara Therapeutics Inc
Soligenix Inc
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Vascular Biogenics Ltd
Xalud Therapeutics Inc